Mexico is an important pharmaceutical market in Latin America, but market entry does not end with obtaining a sanitary registration. Companies marketing medicines and vaccines must maintain an effective pharmacovigilance system to identify, evaluate, and manage potential safety risks throughout a product’s lifecycle.
The Mexican regulatory framework places pharmacovigilance within a broader public-health system overseen by the Federal Commission for the Protection against Sanitary Risks (COFEPRIS). The current framework is primarily based on NOM-220-SSA1-2016, together with subsequent modifications, guidance, and requirements issued by the National Center for Pharmacovigilance (CNFV). COFEPRIS notes that the current applicable framework is NOM-220-SSA1-2016 with its 2020 modification.
Understanding Pharmacovigilance in Mexico
Pharmacovigilance is concerned with detecting, identifying, quantifying, evaluating, and preventing potential risks associated with medicines and vaccines.
Mexico has progressively strengthened its pharmacovigilance framework. COFEPRIS explains that NOM-220-SSA1-2016 replaced the earlier NOM-220-SSA1-2012 and established requirements for the installation and operation of pharmacovigilance activities in Mexico.
The framework is relevant to a broad group of stakeholders, including:
- Marketing authorization holders and their representatives
- Healthcare institutions
- Healthcare professionals
- Research organizations
- Distributors and commercial entities
- Pharmacovigilance units and responsible personnel
COFEPRIS describes pharmacovigilance as a shared responsibility involving stakeholders connected with medicines and vaccines.
For companies entering Mexico, this means pharmacovigilance should be incorporated into the regulatory strategy from the beginning rather than treated as a post-approval administrative requirement.
2. The Role of COFEPRIS and the CNFV
COFEPRIS is Mexico’s federal authority responsible for sanitary regulation, control, and surveillance across multiple health-related sectors, including medicines and medical devices. Its regulatory responsibilities include product authorizations, establishment oversight, importation, advertising, and post-market surveillance.
Within pharmacovigilance, the National Center for Pharmacovigilance (CNFV) plays a central role in coordinating pharmacovigilance activities.
Companies should therefore understand two related dimensions:
Regulatory authorization
Before commercialization, companies need to address applicable regulatory requirements for obtaining and maintaining the relevant sanitary authorization.
COFEPRIS currently provides procedures covering new registrations, modifications, and renewals for medicines and medical devices.
Post-market safety surveillance
Once a product is marketed, safety information must continue to be collected, assessed, documented, and managed.
This creates a continuous connection between regulatory affairs and pharmacovigilance.
For organizations requiring local regulatory support, Regulatory Affairs Services in Mexico can form part of a broader strategy for managing country-specific regulatory activities.
3. Key Pharmacovigilance Responsibilities for Companies
An effective pharmacovigilance system should be capable of receiving safety information from multiple sources and converting that information into appropriate safety actions.
Depending on the product and applicable requirements, companies may need processes covering:
- Adverse event and safety information collection
- Case assessment and processing
- Medical review
- Safety database management
- Regulatory reporting
- Signal detection and evaluation
- Periodic safety activities
- Risk management
- Safety communication
- Literature surveillance
- Pharmacovigilance documentation and quality systems
- Training and oversight of relevant personnel
COFEPRIS also publishes specific requirements concerning the registration, modification, or removal of pharmacovigilance units and responsible personnel.
A key practical consideration is local accountability. A global pharmacovigilance system may provide the overall methodology, database, standard operating procedures, and safety governance, but Mexico-specific responsibilities still need to be clearly mapped.
For organizations without sufficient internal capabilities, Pharmacovigilance Services in Mexico can support the country-specific implementation of pharmacovigilance activities.
4. Why Literature Monitoring Matters
Safety information does not come exclusively from spontaneous reports or clinical studies.
Published scientific literature can provide important evidence about:
- Previously unidentified adverse reactions
- Emerging safety signals
- Drug interactions
- Special populations
- Long-term safety concerns
- Changes in the understanding of an established risk
- New evidence relating to benefit-risk balance
This makes literature surveillance an important component of a mature pharmacovigilance system.
What does effective literature monitoring involve?
A structured process generally includes:
- Defining relevant databases and sources.
- Establishing search strategies based on products and active substances.
- Conducting searches at defined intervals.
- Screening publications for potentially relevant safety information.
- Assessing identified articles.
- Processing reportable cases where applicable.
- Documenting search results and decisions.
- Escalating potential signals for further assessment.
The process should be sufficiently documented to demonstrate that searches were systematic, reproducible, and appropriately assessed.
Companies with global portfolios may also benefit from literature monitoring Services when they need to integrate scientific literature surveillance into a broader safety monitoring framework.
5. Risk Management in the Mexican Market
Pharmacovigilance is not simply about collecting adverse-event information. The ultimate objective is to understand potential risks and determine whether action is necessary.
Risk management may involve:
- Identifying important risks
- Characterizing known and potential risks
- Assessing missing information
- Monitoring emerging safety signals
- Implementing risk minimization measures
- Evaluating the effectiveness of those measures
- Updating safety strategies as evidence changes
This is particularly important for products with complex safety profiles, newly identified risks, or significant uncertainty surrounding specific patient populations.
A lifecycle approach is essential
Risk assessment should not be viewed as a one-time exercise performed immediately after approval.
New evidence can emerge from:
- Routine clinical use
- Post-marketing reports
- Published literature
- Epidemiological research
- Regulatory actions in other countries
- New clinical studies
- Changes in prescribing patterns
Consequently, a company’s risk-management strategy should be capable of evolving with the evidence.
Organizations looking to strengthen this area can consider Pharmacovigilance Risk Management Services as part of a structured safety-management approach.
6. Common Challenges for Global Pharma Companies
Multinational companies frequently encounter several practical challenges when implementing pharmacovigilance processes in Mexico.
1. Translating global procedures into local requirements
A global SOP may provide the foundation, but local regulatory requirements, reporting pathways, responsibilities, and documentation expectations must be assessed separately.
2. Maintaining clear responsibility
Companies should clearly define who is responsible for receiving, assessing, escalating, documenting, and reporting safety information.
Ambiguous ownership can create delays and compliance gaps.
3. Managing multiple information sources
Safety information can originate from healthcare professionals, patients, clinical research, medical information teams, distributors, literature, and other channels.
Each source needs to connect to an appropriate safety workflow.
4. Keeping regulatory knowledge current
Regulatory requirements can evolve through new guidance, amendments, administrative procedures, and regulatory communications.
A process that was compliant several years ago may not remain optimal indefinitely.
5. Connecting regulatory and safety teams
Pharmacovigilance, regulatory affairs, medical affairs, quality, and clinical teams often hold different pieces of the overall safety picture.
Effective governance requires these functions to communicate rather than operate independently.
7. Building an Effective Pharmacovigilance Strategy
A practical Mexico pharmacovigilance strategy should begin with a structured gap assessment.
Companies can evaluate:
Regulatory requirements → Local responsibilities → Safety sources → Reporting processes → Risk management → Quality oversight → Continuous monitoring
A robust system should answer several basic questions:
- Who is responsible for pharmacovigilance activities in Mexico?
- How are safety reports received and documented?
- How quickly are potential cases identified and assessed?
- How are literature searches conducted?
- How are safety signals evaluated?
- How are risks communicated internally?
- How are regulatory changes monitored?
- How are deviations and corrective actions managed?
- How is the effectiveness of the overall system evaluated?
The objective is not to create unnecessary complexity. Instead, the system should provide a reliable connection between safety information, regulatory obligations, scientific evidence, and patient protection.
8. The Role of Regulatory Intelligence and Lifecycle Management
Pharmacovigilance does not operate independently from regulatory affairs.
Regulatory changes in Mexico can influence registration strategies, post-approval activities, safety documentation, labeling considerations, and lifecycle decisions.
For multinational organizations managing products across multiple jurisdictions, regulatory intelligence can help teams identify relevant changes earlier and evaluate their potential business and compliance impact.
Technology can support this process. For example, Regulatory Intelligence Tools can help regulatory teams organize and monitor changing regulatory information across markets.
Similarly, Regulatory Affairs Lifecycle Management tools can support a more connected view of regulatory activities throughout the product lifecycle.
The broader objective should be integration rather than technology for its own sake. Data, regulatory intelligence, pharmacovigilance, and lifecycle management should ultimately help teams make better-informed decisions.
Companies may also work with specialized Life Science Consulting Services when they need support connecting regulatory, pharmacovigilance, and broader market requirements.
Conclusion
Mexico’s pharmacovigilance environment requires pharmaceutical companies to maintain structured and ongoing systems for detecting, evaluating, documenting, and managing potential safety risks.
NOM-220-SSA1-2016, together with its modification and associated COFEPRIS guidance, provides an important foundation for pharmacovigilance activities in Mexico.
However, regulatory compliance should not be viewed as a standalone reporting exercise. Effective pharmacovigilance depends on interconnected processes covering safety reporting, literature surveillance, risk management, regulatory intelligence, quality oversight, and lifecycle decision-making.
For global pharmaceutical companies, the most sustainable strategy is therefore one that combines international pharmacovigilance standards with a clear understanding of Mexico-specific regulatory expectations.